Navigation Links
diaDexus, Inc. Reports 2011 First Quarter Financial Results
Date:5/16/2011

diaDexus' limited revenue and cash resources; the adequacy of the company's intellectual property rights; and diaDexus' significant corporate expenses, including expenses associated with being a public company and real estate liabilities. Additional factors that could cause diaDexus' results to differ materially from those described in the forward-looking statements can be found in diaDexus' most recent annual report on Form 10-K, quarterly report on Form 10-Q, and other reports filed with the Securities and Exchange Commission, and available at the SEC's web site at www.sec.gov. The information set forth herein speaks only as of the date hereof, and diaDexus disclaims any intention and does not assume any obligation to update or revise any forward looking statement, whether as a result of new information, future events or otherwise. -- Tables to follow –DIADEXUS, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except share data)(unaudited)Three Months Ended
March 31,20112010Revenues:  License revenue$

76$

76  Royalty revenue1,005879  Product sales2,2401,512  Product sales to related party—199Total revenues3,3212,666Operating costs and expenses:  Product costs1,132987  Sales and marketing1,1071,278  Research and development1,492932  General and administrative2,114725Total operating costs and expenses5,8453,922Loss from operations(2,524)(1,256)Interest, income expense and other income (expense), net  Interest income173  Interest expense—(112)  Other income —2Loss before income tax(2,507)(1,363)  Income tax (3)(5)Net loss$

(2,510)$

(1,368)Basic and diluted net loss per share:$

(0.05)$

(0.07)Weighted average shares used in computing basic and diluted net loss per share53,067,05719,059,144DIADEXUS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands, except share data)March&#
'/>"/>

SOURCE diaDexus, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. diaDexus, Inc. Adds Two New Directors; Corporate Overview & 3Q Results Webcast Set for November 16, 2010
2. diaDexus, Inc. Reports 2010 Third Quarter Financial Results
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... ., Aug. 22, 2014  Research presented at the ... therapy being developed by Hera Therapeutics Inc. combats three types ... of all cervical cancer. When tested in several ... HPV-18 and HPV-11 cells, according to Louise T. Chow ... the findings at the Seattle conference. ...
(Date:8/22/2014)... /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD), a ... technologies and products for advanced microarray diagnostics, today ... Service Agreement to contract with a UK-based company ... the initial phase of this agreement, SQI will ... of one of the customer,s assays, operational on ...
(Date:8/21/2014)... Ill. , Aug. 21, 2014 ... Baxter International Inc. today announced positive results from ... 855, an investigational, extended half-life recombinant factor VIII ... [Antihemophilic Factor (Recombinant)], which met its primary endpoint ... prophylaxis arm compared to the on-demand arm. ...
Breaking Medicine Technology:Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5
... in combination with the most commonly used doses of ... patients with mixed dyslipidemiaORLANDO, Fla., March 29 Data ... TRILIPIX(R) (fenofibric acid) delayed-release capsules in combination with rosuvastatin ... TRILIPIX 135 mg in combination with rosuvastatin calcium 5 ...
... March 29 A new analysis from the,JUPITER ... the risk of venous thromboembolism (VTE) by 43% ... with low to normal cholesterol levels and elevated,high-sensitivity ... the 58th Annual American College of Cardiology Scientific ...
Cached Medicine Technology:New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 2New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 3New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 4New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 5CRESTOR(R) Reduced Risk of Blood Clots in the Veins 2CRESTOR(R) Reduced Risk of Blood Clots in the Veins 3CRESTOR(R) Reduced Risk of Blood Clots in the Veins 4
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 Mi40x ... uses university-proven research to show people how they can use ... muscle in only a matter of weeks has caught the ... “Ben Pakulski is one of the most well-known bodybuilders in ... the body he has today, that in itself is a ...
(Date:8/22/2014)... Paying tuition and other related educational ... year for four nurse educators pursuing advanced degrees, thanks ... Nursing Foundation for Nursing Education . This year’s recipients ... more than in 2013, thanks to these named NLN ... Isaac Marcil Endowment Funds, both donated by Kathy Mershon; ...
(Date:8/22/2014)... Wisconsin (PRWEB) August 22, 2014 Mueller ... for Plantar Fasciitis, an exciting new product that provides ... you to stay active while you heal. The package ... is truly a new technology – it is not ... , FasciaDerm® PFTape™ System for Plantar Fasciitis ...
(Date:8/22/2014)... A new study of self-awareness by Kessler Foundation ... may be able to improve their self-awareness through ... of print on July 2 in NeuroRehabilitation ... D. Chiaravalloti & John DeLuca: Metacognitive knowledge and ... 10.3233/NRE-141113). Self-awareness is one,s ability to recognize cognitive ...
(Date:8/22/2014)... 2014 Menstrual leaks risk stains and ... Fla., decided that there needed to be a better ... and producible in design variations, the Safety Net optimizes ... which avoids embarrassment and promotes peace of mind. The ... , The original design was submitted to the Fort ...
Breaking Medicine News(10 mins):Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Kessler Foundation study of self-awareness in MS has implications for rehabilitation 2
... gene (MTDH) plays a role in both cancer metastasis ... Press in the January 6th issue of the journal ... therapeutic target for high risk breast cancers. , "Most ... succumb to recurrent tumors that spread to distant vital ...
... , The Fifth International Conference on Cell Therapy ... on stem cells for non-cardiac organ injury. The session ... disease and diabetes, bone marrow cells for stroke patients, ... , Highlights from other sessions include the first human ...
... in the U.S. each year have been exposed to alcohol or ... by the National Center on Substance Abuse and Child Welfare. If ... remain in foster care longer, and chances are very low that ... study led by Joseph P. Ryan, a faculty member in the ...
... PR Newswire Staff Volunteer Time As Part ... InitiativeCLEVELAND, Jan. 5 Ronald McDonald House of ... two non-profit organizations serving the Cleveland community, were ... hours from PR Newswire,s Cleveland staff in 2008, ...
... cost Medicaid hundreds of millions of dollars annually in ... could not only improve outcomes but also save substantial ... examined records of nearly 150,000 people in six states. ... more than they think," said Robin E. Clark, PhD, ...
... OF PLASTIC SURGEONSARLINGTON HEIGHTS, Ill., Jan. 5 The ... Plastic Surgeons:Can The US Really Cut Health Care Spending? ... is one of the strongest sectors of the ailing ... health care spending is not probable. The author, who ...
Cached Medicine News:Health News:Gene plays dual role in breast cancers with poor prognosis 2Health News:Conference on cell therapy includes new session on stem cells for non-cardiac organ injury 2Health News:'Recovery coaches' effective in reducing number of babies exposed to drugs 2Health News:'Recovery coaches' effective in reducing number of babies exposed to drugs 3Health News:PR Newswire Provides Grant to Ronald McDonald House and Habitat for Humanity in Cleveland 2Health News:PR Newswire Provides Grant to Ronald McDonald House and Habitat for Humanity in Cleveland 3Health News:PR Newswire Provides Grant to Ronald McDonald House and Habitat for Humanity in Cleveland 4Health News:PR Newswire Provides Grant to Ronald McDonald House and Habitat for Humanity in Cleveland 5Health News:Substance abuse adds millions to Medicaid's total health care costs 2Health News:Substance abuse adds millions to Medicaid's total health care costs 3Health News:Plastic and Reconstructive Surgery...In Brief 2Health News:Plastic and Reconstructive Surgery...In Brief 3
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Kleinert-Kutz Single Skin Hook, Large...
Medicine Products: